Moon at risk? Asteroid the size of Leaning Tower of Pisa might not hit Earth, but odds of it striking the Moon have just increased
In December 2024, astronomers discovered
asteroid 2024 YR4
, a space rock that routinely crosses Earth's orbit. Observations by the
James Webb Space Telescope
(JWST) in May 2024 have refined the asteroid's trajectory, revealing a slightly increased chance of a lunar impact on December 22, 2032, now at 4.3%. While there is no risk of the asteroid impacting Earth in the foreseeable future, scientists are closely monitoring its path and welcome a potential lunar impact as a valuable learning opportunity.
Asteroid 2024 YR4 is estimated to be between 174 and 220 feet in diameter. This is about the size of the Leaning Tower of Pisa.
Early projections indicated a potential Earth collision in 2032, with impact odds peaking at 3.1% in February. Subsequent observations with JWST and ground-based telescopes reduced the Earth impact probability to zero.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Chula Vista: Stunning New 2-Bed Senior Apartments (Take A Peek Inside)
Senior Apartments | Search Ads
Click Here
Undo
The probability of a lunar impact, however, has increased. The initial JWST imaging in March reported a 3.8% chance of a lunar collision.
"As data comes in, it is normal for the impact probability to evolve,"
NASA
representatives wrote in the statement.
Live Events
The asteroid was observed by JWST's Near-Infrared Camera in May. These observations allowed scientists to calculate the space rock's trajectory with greater precision.
The range of possible locations for 2024 YR4 on Dec. 22, 2032, has decreased as NASA gained more data. This improved the certainty of the asteroid's position.
If an asteroid of this size were to impact Earth, it could cause significant damage. It could wipe out a city with the equivalent force of 500 Hiroshima bombs.
A collision with the moon would create a new crater. However, it would not be devastating to Earth's satellite.
Some scientists view a lunar impact as a positive event. It would provide a valuable opportunity to study asteroid impact prediction.
"We've got our fingers crossed for a moon impact," Alan Fitzsimmons , a physics and math professor at Queen's University Belfast in the U.K. who was not involved in the JWST observations, told New Scientist in March.
"It would have no effect on Earth, but would allow us to study the formation of a lunar crater by a known asteroid for the very first time."
The asteroid is currently moving toward the outer solar system. It is beyond the view of Earth-based telescopes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
28 minutes ago
- The Print
How Serum Institute, DNDi tie-up for affordable antibody will bolster global fight against dengue
Additionally, a joint project team will be formed to advance clinical trials, with the goal of registering and deploying the dengue monoclonal antibody in India and other dengue-endemic countries, provided the studies confirm its safety and efficacy, they said in a joint statement. The SII and the Drugs for Neglected Diseases initiative (DNDi) entered into a partnership on 13 June, declaring they will develop a workplan to carry out late stage trials and access activities, along with a joint strategy to raise necessary funds and resources for developing the potential drug candidate, formerly known as VIS513 or Dengueshield. New Delhi: Pune-based Serum Institute of India (SII) has joined hands with an international medical research organisation to accelerate the clinical development of an affordable monoclonal antibody for dengue, a vector-borne disease that has emerged as a major public health challenge for countries like India. Dengue is a climate-sensitive, viral infection transmitted to humans through the bite of infected mosquitoes, mainly aedes aegypti that also spreads pathogens which cause zika and chikungunya fever. While many dengue infections are asymptomatic or produce only mild illness, the virus can in several patients cause more severe disease, and even death. It is estimated that one in 20 people who get sick with dengue get severely ill. Despite the alarmingly rising prevalence and severity of the vector-born disease, there is still no specific treatment available for dengue. The collaboration aims at accelerating the development of an effective and affordable monoclonal antibody treatment for dengue caused by any of the four serotypes of dengue virus, in close cooperation with endemic countries, including Thailand, Malaysia, and Brazil. Despite the… — SerumInstituteIndia (@SerumInstIndia) June 13, 2025 Also Read: India may soon get 1st dengue vaccine, but wait for jab effective against all 4 strains could be longer The latest collaboration The VIS513 is developed by US-based biotechnology company Visterra, a biologic research early-stage clinical development arm of Tokyo-based Otsuka Pharmaceuticals. The VIS513 was later licensed to the SII. The SII has carried out phase 1 and phase 2 trials of the therapy in India, proving its safety and efficacy in a small number of humans. Currently, the pivotal Phase III clinical trial is underway in India, and the collaboration paves way for the expansion of the drug candidate in several other countries where dengue is endemic, the two entities said. Dengue poses a significant threat, with 3.9 billion people at risk and cases more than doubling each year since 2021. The World Health Organization says the actual number of dengue cases globally rose from 5,05,430 cases in 2000 to 5.2 million in 2019. India is among the top 30 countries with the highest burden of dengue, and according to government estimates, among the 20-25 percent of cases where dengue symptoms are clinically apparent, children are at a significantly higher risk of hospitalisation and mortality. This year, the country registered 12,043 dengue cases and six deaths till March, according to the National Centre for Vector Borne Disease Control statistics. Last year, 2,33,519 cases and 297 deaths were reported but experts underline the actual burden of the disease is much higher. 'India reports tens of thousands of dengue cases every year, with outbreaks occurring every two to three years in different states,' said Dr Kavita Singh, the Asia Continental Lead & Director South Asia, DNDi. What is deeply concerning is that dengue is no longer confined to historically endemic regions but is rapidly expanding into newer states, she added. 'Addressing this growing threat demands a multi-pronged approach, including strengthened vector control, surveillance, community awareness and, critically, the development of effective treatments and diagnostics,' Singh also said. A 2024 dengue bulletin by the WHO said that the highest number of dengue cases was recorded in 2023, affecting over 80 countries in all regions of the WHO. In 2023, a combination of ongoing dengue transmission and a significant surge in cases led to a record-breaking 6.5 million infections and over 7,300 deaths globally. New monoclonal antibody offers help Monoclonal antibodies, sometimes also called passive immunisation, are special types of proteins called antibodies which are made in laboratories. Dengue is caused by any of four dengue virus (DENV) serotypes (DENV 1 to 4), each of which can cause minor dengue fever or severe dengue. Dengue can be anything from an infection without symptoms, a mild fever or a severe fever with musculoskeletal pain to haemorrhagic fever (low platelets leading to bleeding) and dengue shock syndrome (severe form of dengue infection that can lead to circulatory collapse). The latter two can be very severe and result in death if not recognised and treated early. And these two conditions usually happen, not in the first but in subsequent infection, when the dengue virus strain is different from the one that caused the earlier infection. According to Dr R.R. Dutta, the head of internal medicine with Paras Health in Gurugram, medical practitioners need to develop customised treatment plans which focus on avoiding severe disease outcomes such as dengue hemorrhagic fever and shock syndrome in patients who experience severe symptoms. Dr Manisha Arora, director, internal medicine with C K Birla Hospital in Delhi, pointed out that unlike bacterial infections, where antibiotics can attack the root cause and cure the disease, dengue, being a viral infection, lacks such a targeted treatment. If we had a specific antiviral for dengue, it would help in directly attacking the virus, thereby reducing the risk of complications and improving patient outcomes, said the clinician. 'Unfortunately, in the absence of such antivirals, doctors are limited to providing only supportive care, such as fluid management, monitoring vital signs, and treating complications as they arise,' Arora stressed. The current treatment regime for severe dengue patients depends heavily on early detection and timely intervention, but it doesn't address the underlying virus. 'The lack of specific antivirals limits our ability to prevent disease progression, especially in severe cases. If an effective antiviral existed, it could potentially reduce hospitalisations, lower the risk of long-term health issues and ultimately save more lives,' Arora also said. The monoclonal antibody candidate by the SII, as per available information, has shown efficacy against all dengue virus serotypes with no serious adverse events. The therapy candidate, designed to be effective against all four DENV serotypes, works by binding to a specific part of DENV called the envelope protein domain III, known for its role in viral entry into host cells and its immunogenicity. The results from a phase 1 clinical trial of the drug involving 40 participants in India—based on follow-ups lasting 85 days—whihc was published in the Lancet last year, showed the drug was found effective and safe in early testing. AV-1, another investigational human monoclonal antibody developed by US-based company AbViro, is also in a similar stage of development and is undergoing safety and efficacy trials across various countries. A dengue vaccine by Japanese pharma giant Takeda, approved by some other countries, is also undergoing trials in India to generate local safety and efficacy data ahead of its regulatory approval in the country. (Edited by Ajeet Tiwari) Also Read: India sees alarming rise in dengue cases even before peak season, steady increase over past 4 years
NDTV
2 hours ago
- NDTV
US Firm Uses Fungi To Develop Formula To Break Plastic In Baby Diapers
A US-based start-up has come up with a sustainable solution for environmental issues linked to disposable diapers. The company, Hiro Technologies, said that they have developed MycoDigestible Diapers, which is a fungi-powered decomposition technology. The Texas startup company said that baby poop and fungi would work together to break down the plastic. "We have figured out how to collaborate with nature's ancient technology — decomposer fungi — to support the breakdown of the HIRO Diaper," the website of Hiro Technologies noted. How will this disposable diaper work? The company said that each MycoDigestible Diaper comes with a packet of fungi, which is supposed to be added to the dirty diaper before throwing it away. The fungi are activated by moisture from faeces, urine and the environment to begin the process of biodegradation after a week or two. The company is selling "diaper bundles" for $35 a week online. Disposable diapers contribute significantly to landfill waste, taking up to 300-500 years to decompose. They emit greenhouse gas methane and contaminate groundwater. If not disposed of properly, the diapers can also pollute water bodies and spread viruses and bacteria. The company said that they analysed the stages of decomposition of a treated diaper over time in three sealed jars. The product looked like black soil in nine months. Scientists have conducted several studies to understand various aspects of fungi. Earlier this year, in February, a study found that a Hawaiian marine fungus is capable of plastic degradation. Researchers at Yale University in 2011 identified a fungus (Pestalotiopsis microspora) that is capable of consuming polyurethane, a plastic polymer. Drawbacks of using diapers Several health experts have said that chemicals and synthetic materials in disposable diapers can cause skin irritation, allergic reactions and rashes. Infrequent changing and prolonged exposure to urine and stool can lead to diaper rash, regardless of the diaper type.
Time of India
2 hours ago
- Time of India
‘Of Course I Still Love You…': No, it's not a love song — it's Elon Musk's droneship that catches falling rockets
It sounds like something your lover might text you at 2 a.m., or maybe the name of a Taylor Swift album. But 'Of Course I Still Love You' isn't about heartbreak; it's about hardware. Big, flaming, hardware falling from space. No, this isn't a Nicholas Sparks sequel. It's the name of one of SpaceX 's autonomous drone ships that literally catches rockets. Imagine a robot butler crossed with a landing pad, floating in the Pacific, whispering 'come home, baby' to tired Falcon 9 boosters. And the kicker? The name isn't Musk being melodramatic. It's a tribute to Iain M. Banks' sci-fi novels, where sentient starships have names that sound like sarcastic tweets. One is even called "No More Mr. Nice Gaius." In a world where billionaires build rocket ships and quote sci-fi for fun, 'Of Course I Still Love You' is not a love song. It's an interplanetary punchline that lands rockets. Why Elon Musk gave this name to the rocket lander Elon Musk didn't just wake up one day and decide to name his drone ship like a Taylor Swift B-side. The name comes from the Culture series by author Iain M. Banks, where massive sentient spaceships have delightfully eccentric names like 'You Would If You Really Loved Me' and 'So Much for Subtlety.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like What She Did Mid-Air Left Passengers Speechless medalmerit Learn More Undo Musk, a big Banks fan, borrowed 'Of Course I Still Love You' as a loving geek tribute. Because if you're going to catch space junk mid-air, might as well do it with emotional flair. What exactly is ' Of Course I Still Love You '? Despite the dramatic name, Of Course I Still Love You (OCISLY) is a giant floating landing pad, technically known as an Autonomous Spaceport Drone Ship (ASDS). It's a modified barge outfitted with robotic precision and steel arms of destiny that help recover Falcon 9 first-stage boosters after launch. Located off the West Coast at Long Beach, California, it's essentially the oceanic version of a space parking valet. The booster detaches from the rocket, flips itself mid-air like a gymnast, fires retro thrusters, and lands gently—on a ship that's floating. On water. While moving. In waves. It's like trying to land a skyscraper on a surfboard. Why catch rockets anyway? Because rocket boosters are expensive. Like, really expensive. Instead of tossing them into the ocean after every launch (as was standard practice for decades), SpaceX's whole business model thrives on reusability. By landing and reusing boosters, the company saves hundreds of millions of dollars and reduces waste—kind of like upcycling, but instead of mason jars, it's billion-dollar rocket stages. Plus, it looks awesome on livestreams. Nothing says 'future' like a 16-story rocket doing a slow, graceful ballet move onto a floating pad with a romantic name. Sibling ships and more sentiment OCISLY isn't alone. Its East Coast sibling is called 'Just Read the Instructions', also a Banks reference, because apparently even rocket landings need passive-aggressive reminders. These ships are part of the ASDS fleet and are key players in SpaceX's vision of rapid, cost-effective space travel. Imagine: your rocket takes off from Florida, launches a satellite, does a quick pirouette in the stratosphere, then lands back on a boat named like it just got out of therapy. When sci-fi becomes science fact The sheer absurdity of naming high-tech rocket-catching machines after fictional spaceships with emotional baggage is peak Musk. But beneath the quirk lies serious innovation. These drone ships have helped SpaceX pull off over 270 booster landings and counting. They've turned what once looked like a Michael Bay explosion into a controlled, reusable, economically viable maneuver. In short: they make science fiction real. And do it with names that make engineers and English majors equally happy. Love, rockets, and a whole lot of nerdiness So, next time you see a Falcon 9 rocket descend from space and land upright on a tiny square in the middle of the ocean, remember—it's not just landing. It's being welcomed by a giant, floating robot that says: Of Course I Still Love You. Because nothing says progress like marrying sci-fi references with real-world rocket science. Elon Musk didn't just build a space empire—he made it poetic, one oddly-named barge at a time.
